Corium to Report Third Quarter Fiscal Year 2016 Financial Results on Thursday, August 4, 2016
July 28 2016 - 8:00AM
Corium International, Inc. (NASDAQ:CORI) today announced that it
will report financial results for the third fiscal quarter ended
June 30, 2016 on Thursday, August 4, 2016 after the close of
the U.S. financial markets. Corium will host a conference
call and live audio webcast at 5:00 p.m. Eastern time, 2:00
p.m. Pacific time to discuss its financial results and
recently announced clinical and regulatory developments.
Conference Call and Webcast Details
Investors and analysts can access the call toll-free by dialing
(844) 831-3024 (United States) or +1 (315) 625-6887
(international). The conference ID# is 56382169. The
conference call will also be available via a live audio webcast on
the Investors section of Corium’s website
at http://ir.coriumgroup.com/events.cfm. Please access
the website 10 minutes prior to the start of the call to ensure
adequate time for any software downloads that may be
necessary. A replay of the conference call will be available
for two weeks and may be accessed by visiting Corium’s website.
About Corium
Corium International, Inc. is a commercial-stage
biopharmaceutical company focused on the development, manufacture
and commercialization of specialty pharmaceutical products that
leverage the company's broad experience with advanced transdermal
and transmucosal delivery systems. Corium has multiple
proprietary programs in preclinical and clinical development,
focusing primarily on the treatment of neurological disorders, with
lead programs in Alzheimer's disease. Corium has developed
and is the sole commercial manufacturer of seven prescription drug
and consumer products with partners Teva Pharmaceuticals, Endo
Pharmaceuticals and Procter & Gamble. The company has two
proprietary transdermal platforms: Corplex™ for small molecules and
MicroCor®, a biodegradable microstructure technology for small
molecules and biologics, including vaccines, peptides and
proteins. The company's late-stage pipeline includes a
contraceptive patch co-developed with Agile Therapeutics that is
currently in Phase 3 trials, and additional transdermal products
that are being developed with other partners. For further
information, please visit www.coriumgroup.com.
Corplex™ and MicroCor® are registered trademarks of Corium
International, Inc.
Investor and Media Contacts:
BCC Partners
Karen L. Bergman
kbergman@bccpartners.com
(650) 575-1509
Susan Pietropaolo
spietropaolo@bccpartners.com
(845) 638-6290
CORIUM INTERNATIONAL, INC. (NASDAQ:CORI)
Historical Stock Chart
From Mar 2024 to Apr 2024
CORIUM INTERNATIONAL, INC. (NASDAQ:CORI)
Historical Stock Chart
From Apr 2023 to Apr 2024